Doctors Attest to Advanced Energy Technology Device’s
Transformative Solutions to Achieve Desired Results in Patients

CLEARWATER, FL — September 13, 2022 – Apyx® Medical Corporation (NASDAQ: APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the release of a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology.

Leading plastic surgeons across the country are sharing the transformative results they’ve achieved using Renuvion, a proprietary helium plasma and radiofrequency technology, on patients for cosmetic procedures in their practices.

In a video featuring celebrity plastic surgeon and co-host of the hit television series, ‘Botched’  Dr. Paul Nassif, New York City facial surgeon Dr. Tabasum Mir, Beverly Hills plastic and reconstructive surgeon Dr. Leif Rogers and board certified plastic surgeon Dr. Gregory Buford of Denver, CO, doctors reveal the unmatched benefits of using Renuvion technology in their cosmetic/aesthetic procedures.

In the video Dr. Nassif discloses that his practice uses the device four-to-five times a week in cosmetic procedures. Dr. Mir states that she gets impressive tissue contraction in areas she previously was only able to achieve through surgery, while Dr. Rogers testifies that he has tried every device on the market, and now only uses Renuvion for his procedures because it’s far superior to those other devices. Finally, Dr. Buford declares he’d stake his reputation on the safety and effectiveness of Renuvion.

Watch the video here:
Renuvion Review | Top Plastic Surgeons Talk Cutting-Edge Technology – YouTube

Renuvion is the only product that is FDA-cleared to improve the appearance of lax (loose) skin on the neck and submental region (chin). It was also recently cleared for specific dermatological procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II or III. These clearances highlight the safety and efficacy of the Renuvion technology.

To date, hundreds of physicians across the U.S. use Renuvion in their practices. For a list, by state, of physicians using the device visit: https://renuvionfinder.com.

For additional information visit Renuvion.com.

About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision while minimizing unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, any statements regarding the potential impact of the COVID-19 pandemic and the actions by governments, businesses and individuals in response to the situation; projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration, supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the U.S. Food and Drug Administration and other governmental and regulatory bodies, both domestically and internationally; the impact of the recent FDA Safety Communication on our business and operations; factors relating to the effects of the COVID-19 pandemic; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

# # #

Media Contact:
Jane Sparango
Coterie Media on behalf of Apyx Medical Corporation
jane@coteriemedia.com
310-339-1214

Investor Relations Contact:
ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com